Cardiac diagnostics company Tricog Health, in collaboration with Japanese electronics giant Omron Healthcare, has launched KeeboHealth, a next-generation connected health platform aimed at transforming remote cardiac care in India and beyond.
The KeeboHealth platform leverages advanced artificial intelligence, real-time data analytics, and home-based monitoring tools to support timely and personalized management of cardiovascular conditions. The platform integrates seamlessly with Omron’s connected devices—including home ECG monitors, blood pressure monitors, and smart weighing scales—to provide a comprehensive view of patient health and enable tailored clinical decisions.
With this initiative, Tricog has set an ambitious target: to screen an additional 73 million people by 2030, aiming to reach a total of 100 million individuals screened for heart disease.
“KeeboHealth is not just a digital solution—it’s a lifeline for millions living with heart failure,” said Dr. Charit Bhograj, CEO and Founder of Tricog Health. “Our AI continuously analyzes patient data to detect early warning signs, enabling timely interventions even in regions where specialist access is limited. Our goal is to reduce cardiovascular mortality in India by 33%.”
According to Tricog, nearly 3 million people in India die annually due to heart-related conditions. By enabling proactive, at-home cardiac care, the company hopes to bridge gaps in access and affordability, especially in underserved areas.
Tricog has so far raised $25 million to strengthen its AI capabilities and fuel expansion. The company is working closely with six Indian state governments—including Goa, Maharashtra, Telangana, Bihar, Karnataka, and another unnamed state—to expand the deployment of its AI-driven heart care solutions.
On the global front, Tricog is already active in Southeast Asia and East Africa, reinforcing its vision of making quality cardiac care accessible in emerging markets.
Dr. Bhograj also emphasized that hypertension remains a major contributor to cardiovascular disease. India’s blood pressure monitoring market is sizeable, with around 250 million individuals in need of regular monitoring. Omron, a key player in this segment, offers a range of healthcare devices including BP monitors, nebulizers, thermometers, body composition analyzers, and TENS devices.
Addressing ongoing concerns about the safety of COVID-19 vaccines and cardiac events, Dr. Bhograj firmly dismissed the speculation:
“Vaccines do not cause heart attacks. There may be rare allergic reactions, but they are overwhelmingly safe. If anything, COVID itself has weakened many immune systems and may contribute to heart complications—not the vaccines.”
Omron Healthcare, which operates in 130 countries, continues to strengthen its India presence. The company reported 3–4% sales growth in FY24, and inaugurated a new manufacturing plant in Chennai in March 2025. China remains a key market, contributing about 30% of Omron’s global sales.
While pricing details for KeeboHealth have not been officially released, Tricog has indicated that the platform will be affordably priced to ensure broad accessibility across income segments.